← Back to headlines
Neurocrine Nears $2.5 Billion Acquisition Deal for Soleno Therapeutics
Neurocrine Biosciences is reportedly close to finalizing a deal to acquire Soleno Therapeutics. The potential acquisition is valued at over $2.5 billion, according to reports from the Financial Times.
6 Apr, 02:47 — 6 Apr, 03:20
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
FT
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US1UK1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
FTVery High1h ago
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
Read full article →seeking-alphaMixed1h ago
Neurocrine nears $2.5B-plus deal to buy Soleno Therapeutics - FT
Read full article →Coverage Timeline
First report: FT · 6 Apr, 02:47|Full coverage: 2 · 34m|Window: 34m
Left-leaningCenterRight-leaning
